TCL1B Human

T-cell Leukemia/Lymphoma 1B Human Recombinant
Cat. No.
BT11187
Source
Escherichia Coli.
Synonyms
T-Cell Leukemia/Lymphoma 1B, Oncogene TCL-1B, Syncytiotrophoblast-Specific Protein, SYN-1, TML1, T-Cell Leukemia/Lymphoma Protein 1B, T-Cell Lymphoma/Leukemia 1B, TCL1/ MTCP1-Like 1, TCL1, Oncogene TCL1B, TCL1/MTCP1-Like Protein 1.
Appearance
Sterile Filtered clear solution.
Purity
Greater than 95% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

TCL1B Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 151 amino acids (1-128a.a) and having a molecular mass of 17.2kDa. TCL1B is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
T-cell leukemia/lymphoma 1B, also known as TCL1B, is a member of the TCL1 family. It is expressed in various tissues, including the placenta and testis. TCL1B enhances the phosphorylation and activation of AKT1 and AKT2.
Description
Recombinant human TCL1B protein was produced in E. coli. It is a single, non-glycosylated polypeptide chain consisting of 151 amino acids (1-128a.a) and has a molecular weight of 17.2 kDa. The TCL1B protein is fused to a 23 amino acid His-tag at the N-terminus and is purified using proprietary chromatographic techniques.
Physical Appearance
A clear, sterile-filtered solution.
Formulation
The TCL1B protein solution (0.5 mg/ml) is supplied in a buffer containing 20 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 40% glycerol, and 2 mM DTT.
Stability
The product can be stored at 4°C for 2-4 weeks. For longer storage periods, it is recommended to freeze the product at -20°C. To ensure stability during long-term storage, adding a carrier protein (0.1% HSA or BSA) is recommended. Avoid repeated freeze-thaw cycles.
Purity
The purity of TCL1B protein is greater than 95% as determined by SDS-PAGE analysis.
Synonyms
T-Cell Leukemia/Lymphoma 1B, Oncogene TCL-1B, Syncytiotrophoblast-Specific Protein, SYN-1, TML1, T-Cell Leukemia/Lymphoma Protein 1B, T-Cell Lymphoma/Leukemia 1B, TCL1/ MTCP1-Like 1, TCL1, Oncogene TCL1B, TCL1/MTCP1-Like Protein 1.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMASEASV RLGVPPGRLW IQRPGIYEDE EGRTWVTVVV RFNPSRREWA RASQGSRYEP SITVHLWQMA VHTRELLSSG QMPFSQLPAV WQLYPGRKYR AADSSFWEIA DHGQIDSMEQ LVLTYQPERK D

Product Science Overview

Introduction

T-cell Leukemia/Lymphoma 1B (TCL1B) is a protein that plays a significant role in the development and progression of certain types of leukemia and lymphoma. This protein is part of the TCL1 family, which includes TCL1A, TCL1B, and MTCP1. These proteins are known for their involvement in the regulation of T-cell proliferation and survival. The recombinant form of TCL1B, referred to as Human Recombinant TCL1B, is produced through recombinant DNA technology, allowing for its use in various research and therapeutic applications.

Structure and Function

TCL1B is a small protein composed of approximately 114 amino acids. It shares a high degree of homology with other members of the TCL1 family, particularly TCL1A. The protein is characterized by its ability to form homodimers and heterodimers, which are essential for its function. TCL1B interacts with several key signaling molecules, including AKT (protein kinase B), which is crucial for cell survival and proliferation.

The primary function of TCL1B is to enhance the activation of AKT. This activation leads to the promotion of cell survival and proliferation, particularly in T-cells. By interacting with AKT, TCL1B helps to prevent apoptosis (programmed cell death) and supports the growth and division of T-cells. This function is particularly relevant in the context of T-cell leukemia and lymphoma, where uncontrolled cell proliferation is a hallmark of the disease.

Role in Disease

TCL1B has been implicated in the pathogenesis of several types of T-cell malignancies, including T-cell prolymphocytic leukemia (T-PLL) and adult T-cell leukemia/lymphoma (ATL). Overexpression of TCL1B has been observed in these diseases, suggesting that it plays a role in their development and progression. The protein’s ability to enhance AKT activation is believed to contribute to the uncontrolled proliferation of malignant T-cells.

In addition to its role in T-cell malignancies, TCL1B has also been studied in the context of other cancers, such as B-cell lymphomas and solid tumors. Its involvement in these diseases highlights the broader significance of TCL1B in cancer biology.

Research and Therapeutic Applications

The recombinant form of TCL1B, Human Recombinant TCL1B, is produced using recombinant DNA technology. This involves the insertion of the TCL1B gene into a suitable expression system, such as bacteria or mammalian cells, to produce the protein in large quantities. The availability of recombinant TCL1B has facilitated numerous research studies aimed at understanding its function and role in disease.

In the research setting, Human Recombinant TCL1B is used to study the molecular mechanisms underlying T-cell leukemia and lymphoma. It is also employed in drug discovery efforts to identify potential therapeutic targets for these diseases. By elucidating the pathways regulated by TCL1B, researchers hope to develop novel treatments that can inhibit its function and thereby control the proliferation of malignant cells.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.